This fall, COTA’s CEO Mike Doyle attended the Healthcare Leaders Conference in Dallas, TX, and the Future of Health Data Summit 2019 in Washington, DC. In his conversations, a few key takeaways stood out around innovations related to the use of meaningful data…

We are pleased to recognize Tanvi Pal in this month’s Team Member Spotlight! If you’re interested in learning more about Tanvi, why she likes working at COTA and her thoughts on the future of cancer care, read on…

The TAILORx study was a major landmark in setting a new standard of care for breast cancer patients. But how well do real world treatment and outcomes mirror that of the clinical trial?

COTA’s medical and scientific teams recently participated in the 8th Annual Friends of Cancer Research Blueprint for Breakthrough Forum in Washington, DC with various stakeholders across the regulatory and RWE landscape.

While planning activities for breast cancer awareness month at COTA, Helena Yelovich who works on our medical team, made an impassioned request: “Don’t Ignore Stage 4.” Read more about her story on our blog.

Did you know COTA has a Diversity & Inclusion Committee to foster conversation, collaboration, and education between employees? Learn more about how this group recently celebrated National Celebrate Diversity Month and Pride Month, as well as COTA’s support of the Title VII amicus brief.

Elaborating on the use cases for real-world data, Chris Boone, VP for global medical epidemiology & big data analysis at Pfizer, and Viraj Narayanan, VP of life sciences at COTA, Inc., recently co-authored a STAT+ article that explores how real-world evidence can be used to fuel precision medicine and disrupt increasingly outdated clinical trial models.

The CO10s are back from ASCO 2019! See what Mike Doyle, COTA’s CEO, took away from this year’s conference as it relates to the use of real-world data and evidence in cancer care.

The MMRF announced they are launching CureCloud™, a centralized data hub that generates, aggregates and visualizes data to advance precision medicine to patients living with multiple myeloma. See how COTA is supporting this program!

Learn more about CC Obi-Gwacham in the latest COTA Team Member Spotlight!

In advance of the 2019 ASCO Annual Meeting, members of COTA’s medical leadership team offer predictions for this year’s conference on topics including the role of precision medicine and RWE in oncology care.

As a company that builds solutions that analyze real-world data to deliver clinically relevant insights that improve cancer care, we want to step back and feature the wonderful COTA team members (called CO10s) who are helping us achieve this goal. This week, we’re featuring Emily Di Capua, our VP of Strategic Initiatives.

Earlier this month, Dr. Scott Gottlieb, the popular FDA Commissioner, announced he is resigning. COTA’s blog explores what this means for the future of RWE and the FDA.

COTA’s CEO Mike Doyle highlights his key takeaways from HIMSS19 around data stockpiling, thinking like consumers, and precision medicine.

It’s no secret that oncology care is at a turning point, but what does this mean for patient care? COTA’s VP of Life Sciences Viraj Narayanan explores the impact and what we can expect in the future.

The American Cancer Society announced promising news to start off 2019 – the overall nationwide cancer death rate has fallen continuously over the last 25 years. What changes have led to this decline?